Sanofi-Aventis Licenses CureDM's Early-Stage Diabetes Compound To Bolster Pipeline
This article was originally published in The Pink Sheet Daily
Executive Summary
Privately-held CureDM could receive up to $335 million in payments, plus sales royalties, from Sanofi-Aventis.
You may also be interested in...
A New Collaborative Model? Janssen Joins Evotec And Harvard To Advance Regenerative Diabetes Projects
Germany's drug discovery services company Evotec has formed a tight bond with Harvard researchers, with both parties expected to share the rewards of their CureBeta pancreatic beta-cell regeneration project if new strategic partner Janssen Pharmaceuticals develops new diabetes therapies from their research.
Sanofi-Aventis Takes Rights to Metabolex's Diabetes Compound
As it continues to diversify away from its juggernaut Lantus, Sanofi takes a chance on a potential first-in-class drug not yet through Phase II.
Sanofi-Aventis Takes Rights to Metabolex's Diabetes Compound
As it continues to diversify away from its juggernaut Lantus, Sanofi takes a chance on a potential first-in-class drug not yet through Phase II.